Please note that masks must still be worn within NYOH practices regardless of vaccination status.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

PH3 Dara/Len vs Len NDMM

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Disease Types: Multiple Myeloma,&nbs

Available at: {clinical_trial_location backspace="7"}PH3 Dara/Len vs Len NDMM, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}